Fremanezumab
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Fremanezumab: From Migraine Prevention to Migraine with Brainstem Aura
One-Sentence Summary
Fremanezumab is a humanized anti-CGRP (calcitonin gene-related peptide) monoclonal antibody, established as a preventive treatment for episodic and chronic migraine. The TxGNN model predicts it may also be effective for Migraine with Brainstem Aura, but this direction is currently supported only by 20 publications (mostly preclinical/mechanistic and observational studies) and no registered clinical trials specific to this subtype.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Migraine prevention (episodic/chronic migraine) — inferred from literature evidence in this pack |
| Predicted New Indication | Migraine with Brainstem Aura |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L3 |
| EU Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from DrugBank (Data Gap DG002). Based on the literature in this evidence pack, fremanezumab is a fully humanized monoclonal antibody (IgG2Δa) that selectively binds and neutralizes CGRP, a key mediator in migraine pathophysiology (PMID 30725283, PMID 28642283). It is established as a preventive therapy for episodic and chronic migraine, including in patients with and without aura or associated neurological dysfunction (PMID 35302681).
Migraine with brainstem aura is a migraine subtype whose aura component is thought to arise from cortical spreading depression (CSD), a wave of neuronal depolarization distinct from the trigeminovascular pain mechanism that fremanezumab primarily targets. Because both conditions fall under the broader migraine spectrum and share overlapping neurovascular pathways, a mechanistic link is biologically plausible.
However, the strongest mechanistic evidence available here is actually cautionary rather than confirmatory: animal studies show fremanezumab does not significantly affect CSD-induced arterial dilatation or plasma protein extravasation (PMID 31127003), and while it can slow CSD propagation and shorten cortical recovery time, it does not prevent CSD from occurring (PMID 31895266). Clinical literature on anti-CGRP antibodies in aura subtypes (including hemiplegic migraine, PMID 41618146, PMID 40264646) remains limited to case reports and small observational series, with efficacy in aura-specific presentations still largely unproven.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 30725283 | 2019 | Review | Handbook Exp Pharmacol | CGRP is a central mediator in migraine pathophysiology, including the aura subgroup; foundational mechanistic rationale for anti-CGRP therapy |
| 35302681 | 2022 | Cohort (post-hoc of Phase 3b FOCUS RCT) | European Journal of Neurology | Fremanezumab showed efficacy and quality-of-life benefits in difficult-to-treat migraine patients with and without aura/neurological dysfunction subgroups |
| 31127003 | 2019 | Preclinical/Animal | J Neuroscience | CSD-induced arterial dilatation and plasma protein extravasation were unaffected by fremanezumab, questioning CGRP’s causal role in aura itself |
| 31895266 | 2020 | Preclinical/Animal | Pain | Fremanezumab slowed CSD propagation rate and shortened cortical recovery but did not prevent CSD occurrence in rats with compromised blood-brain barrier |
| 28642283 | 2017 | Preclinical/Animal | J Neuroscience | Demonstrated selective inhibition of trigeminovascular neurons by fremanezumab — core mechanistic basis for its anti-migraine effect |
| 35268319 | 2022 | Case Report/Review | Journal of Clinical Medicine | Reviewed anti-CGRP mAbs (including fremanezumab) in migraine aura; noted evidence for aura prevention specifically is still scarce |
| 38332541 | 2024 | Observational Case Series | CNS Neurosci Ther | Limited clinical evidence available on anti-CGRP mAb effectiveness specifically for preventing migraine with aura |
| 41618146 | 2026 | Individual Patient Analysis | The Journal of Headache and Pain | Evaluated anti-CGRP mAb effectiveness/safety in hemiplegic migraine (an aura subtype); this population is systematically excluded from RCTs |
| 40264646 | 2025 | Case Report/Review | Frontiers in Neurology | Case report plus literature review on anti-CGRP mAb efficacy in hemiplegic migraine; role in this aura subtype remains largely unexplored |
| 35775208 | 2022 | Observational | Cephalalgia | Assessed effects of erenumab, fremanezumab and galcanezumab on migraine prodromal, accompanying, and central symptoms |
EU Market Information
Fremanezumab is currently not marketed and has 0 recorded marketing authorizations in the available regulatory dataset.
Safety Considerations
Please refer to the SmPC for safety information. (Key warnings, contraindications, and drug interaction data are not available in this evidence pack — this is flagged as a Blocking data gap, see Conclusion.)
Conclusion and Next Steps
Decision: Hold
Rationale: The predicted indication (migraine with brainstem aura) has no registered clinical trials, and the most mechanistically direct evidence available — animal CSD models — indicates fremanezumab does not reliably block the underlying aura mechanism. Combined with a Blocking data gap on TFDA-equivalent safety labeling (warnings/contraindications), the evidence does not yet support progressing this candidate.
To proceed, the following is needed:
- TFDA (or equivalent) label data — warnings and contraindications (Data Gap DG001, Blocking; source: agency label PDF)
- DrugBank-sourced mechanism of action detail (Data Gap DG002, High; source: DrugBank API)
- Dedicated clinical trials or prospective studies in migraine-with-aura/brainstem-aura populations, rather than post-hoc subgroup or case-series data
- Monitoring of emerging hemiplegic/aura-subtype case literature (e.g., PMID 41618146, 40264646) for signal strengthening
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.